Zobrazeno 1 - 10
of 121
pro vyhledávání: '"Issa GC"'
Autor:
Sasaki, K, Ribera, JM, Figueroa, M, Ravandi, F, Short, NJ, Garcia-Manero, G, Daver, NG, Kadia, TM, Konopleva, MY, Jain, N, Issa, GC, Estrov, ZE, Garris, R, Khouri, R, Nasnas, P, DiNardo, CD, Naqvi, K, Kornblau, SM, Montalban-Bravo, G, Pemmaraju, N, Cortes, JE, O'Brien, SM, Chandra, J, Kantarjian, HM, Jabbour, E
Publikováno v:
Blood
r-IGTP. Repositorio Institucional de Producción Científica del Instituto de Investigación Germans Trias i Pujol
instname
r-IGTP. Repositorio Institucional de Producción Científica del Instituto de Investigación Germans Trias i Pujol
instname
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=RECOLECTA___::0fac2aac8bb0efb1b37881720e4a7a3e
https://fundanet.igtp.cat/Publicaciones/ProdCientif/PublicacionFrw.aspx?id=2982
https://fundanet.igtp.cat/Publicaciones/ProdCientif/PublicacionFrw.aspx?id=2982
Autor:
Gener-Ricos G; Department of Leukemia, The University of Texas MD Anderson Cancer Center, Houston, Texas, USA., Bataller A; Department of Leukemia, The University of Texas MD Anderson Cancer Center, Houston, Texas, USA., Rodriguez-Sevilla JJ; Department of Leukemia, The University of Texas MD Anderson Cancer Center, Houston, Texas, USA., Chien KS; Department of Leukemia, The University of Texas MD Anderson Cancer Center, Houston, Texas, USA., Quesada AE; Department of Hematopathology, The University of Texas MD Anderson Cancer Center, Houston, Texas, USA., Almanza-Huante E; Department of Leukemia, The University of Texas MD Anderson Cancer Center, Houston, Texas, USA., Hammond D; Department of Leukemia, The University of Texas MD Anderson Cancer Center, Houston, Texas, USA., Sasaki K; Department of Leukemia, The University of Texas MD Anderson Cancer Center, Houston, Texas, USA., DiNardo C; Department of Leukemia, The University of Texas MD Anderson Cancer Center, Houston, Texas, USA., Kadia T; Department of Leukemia, The University of Texas MD Anderson Cancer Center, Houston, Texas, USA., Daver N; Department of Leukemia, The University of Texas MD Anderson Cancer Center, Houston, Texas, USA., Borthakur G; Department of Leukemia, The University of Texas MD Anderson Cancer Center, Houston, Texas, USA., Issa GC; Department of Leukemia, The University of Texas MD Anderson Cancer Center, Houston, Texas, USA., Short NJ; Department of Leukemia, The University of Texas MD Anderson Cancer Center, Houston, Texas, USA., Kanagal-Shamanna R; Department of Hematopathology, The University of Texas MD Anderson Cancer Center, Houston, Texas, USA., Kantarjian HM; Department of Leukemia, The University of Texas MD Anderson Cancer Center, Houston, Texas, USA., Garcia-Manero G; Department of Leukemia, The University of Texas MD Anderson Cancer Center, Houston, Texas, USA., Montalban-Bravo G; Department of Leukemia, The University of Texas MD Anderson Cancer Center, Houston, Texas, USA.
Publikováno v:
Cancer [Cancer] 2024 Oct 15; Vol. 130 (20), pp. 3452-3462. Date of Electronic Publication: 2024 Jun 19.
Autor:
Wang ES; Roswell Park Comprehensive Cancer Center, Buffalo, NY, USA. Electronic address: eunice.wang@roswellpark.org., Issa GC; MD Anderson Cancer Center, Houston, TX, USA., Erba HP; Duke Cancer Institute, Durham, NC, USA., Altman JK; Northwestern University-Robert H Lurie Comprehensive Cancer Center, Chicago, IL, USA., Montesinos P; Hospital Universitari i Politècnic La Fe, Valencia, Spain., DeBotton S; Institut Gustave Roussy Service d'Hématologie Clinique, Paris, France., Walter RB; Fred Hutchinson Cancer Center, Seattle, WA, USA., Pettit K; University of Michigan, Ann Arbor, MI, USA., Savona MR; Vanderbilt-Ingram Cancer Center, Nashville, TN, USA., Shah MV; Mayo Clinic, Rochester, MN, USA., Kremyanskaya M; Icahn School of Medicine at Mount Sinai, New York, NY, USA., Baer MR; University of Maryland Greenebaum Comprehensive Cancer Center, Baltimore, MD, USA., Foran JM; Mayo Clinic Comprehensive Cancer Center, Mayo Clinic, Jacksonville, FL, USA., Schiller G; David Geffen School of Medicine at UCLA, Los Angeles, CA, USA., Adès L; Hôpital Saint-Louis (AP-HP) and Université Paris Cité and Centre d'Investigations Cliniques-Inserm CIC-1427, Paris, France., Heiblig M; Centre Hospitalier Lyon Sud, Lyon, France., Berthon C; Centre Hospitalo-Universitaire Lille, Lille, France., Peterlin P; CHU de Nantes-Hôtel-Dieu, Nantes, France., Rodríguez-Arbolí E; Department of Hematology, Hospital Universitario Virgen del Rocío, Seville Biomedicine Institute (IBiS/CSIC), University of Seville, Seville, Spain., Salamero O; Servei d'Hematologia de l'Hospital Vall d'Hebron i Unitat d'Hematología Experimental del Vall d'Hebron Institut d'Oncología, Facultat de Medicina, Universitat Autònoma de Barcelona, Barcelona, Spain., Patnaik MM; Mayo Clinic, Rochester, MN, USA., Papayannidis C; IRCCS Azienda Ospedaliero-Universitaria di Bologna, Istituto di Ematologia 'Seràgnoli', Bologna, Italy., Grembecka J; University of Michigan, Ann Arbor, MI, USA., Cierpicki T; University of Michigan, Ann Arbor, MI, USA., Clegg B; University of Michigan, Ann Arbor, MI, USA., Ray J; University of Michigan, Ann Arbor, MI, USA., Linhares BM; University of Michigan, Ann Arbor, MI, USA., Nie K; Kura Oncology, Inc, San Diego, CA, USA., Mitra A; Kura Oncology, Inc, San Diego, CA, USA., Ahsan JM; Kura Oncology, Inc, San Diego, CA, USA., Tabachri M; Kura Oncology, Inc, San Diego, CA, USA., Soifer HS; Kura Oncology, Inc, San Diego, CA, USA., Corum D; Kura Oncology, Inc, San Diego, CA, USA., Leoni M; Kura Oncology, Inc, San Diego, CA, USA., Dale S; Kura Oncology, Inc, San Diego, CA, USA., Fathi AT; Massachusetts General Hospital, Harvard Medical School, Boston, MA, USA.
Publikováno v:
The Lancet. Oncology [Lancet Oncol] 2024 Oct; Vol. 25 (10), pp. 1310-1324.
Autor:
Loghavi S; Department of Hematopathology, The University of Texas, MD Anderson Cancer Center, Houston, Texas, USA., Wei Q; Department of Hematopathology, The University of Texas, MD Anderson Cancer Center, Houston, Texas, USA., Ravandi F; Department of Leukemia, The University of Texas, MD Anderson Cancer Center, Houston, Texas, USA., Quesada AE; Department of Hematopathology, The University of Texas, MD Anderson Cancer Center, Houston, Texas, USA., Routbort MJ; Department of Hematopathology, The University of Texas, MD Anderson Cancer Center, Houston, Texas, USA., Hu S; Department of Hematopathology, The University of Texas, MD Anderson Cancer Center, Houston, Texas, USA., Toruner GA; Department of Hematopathology, The University of Texas, MD Anderson Cancer Center, Houston, Texas, USA., Wang SA; Department of Hematopathology, The University of Texas, MD Anderson Cancer Center, Houston, Texas, USA., Wang W; Department of Hematopathology, The University of Texas, MD Anderson Cancer Center, Houston, Texas, USA., Miranda RN; Department of Hematopathology, The University of Texas, MD Anderson Cancer Center, Houston, Texas, USA., Li S; Department of Hematopathology, The University of Texas, MD Anderson Cancer Center, Houston, Texas, USA., Xu J; Department of Hematopathology, The University of Texas, MD Anderson Cancer Center, Houston, Texas, USA., DiNardo CD; Department of Leukemia, The University of Texas, MD Anderson Cancer Center, Houston, Texas, USA., Daver N; Department of Leukemia, The University of Texas, MD Anderson Cancer Center, Houston, Texas, USA., Kadia TM; Department of Leukemia, The University of Texas, MD Anderson Cancer Center, Houston, Texas, USA., Issa GC; Department of Leukemia, The University of Texas, MD Anderson Cancer Center, Houston, Texas, USA., Kantarjian HM; Department of Leukemia, The University of Texas, MD Anderson Cancer Center, Houston, Texas, USA., Medeiros LJ; Department of Hematopathology, The University of Texas, MD Anderson Cancer Center, Houston, Texas, USA., Tang G; Department of Hematopathology, The University of Texas, MD Anderson Cancer Center, Houston, Texas, USA.
Publikováno v:
American journal of hematology [Am J Hematol] 2024 Oct; Vol. 99 (10), pp. 1959-1968. Date of Electronic Publication: 2024 Jul 17.
Autor:
Haddad FG; Department of Leukemia, The University of Texas M.D. Anderson Cancer Center, Houston, Texas, USA., Sasaki K; Department of Leukemia, The University of Texas M.D. Anderson Cancer Center, Houston, Texas, USA., Nasr L; Department of Leukemia, The University of Texas M.D. Anderson Cancer Center, Houston, Texas, USA., Short NJ; Department of Leukemia, The University of Texas M.D. Anderson Cancer Center, Houston, Texas, USA., Kadia T; Department of Leukemia, The University of Texas M.D. Anderson Cancer Center, Houston, Texas, USA., Dellasala S; Department of Leukemia, The University of Texas M.D. Anderson Cancer Center, Houston, Texas, USA., Cortes J; Georgia Cancer Center, Augusta University, Augusta, Georgia, USA., Nicolini FE; Department of Clinical Hematology and INSERM U1052, CRCL, Centre Leon Bérard, Lyon, France., Issa GC; Department of Leukemia, The University of Texas M.D. Anderson Cancer Center, Houston, Texas, USA., Jabbour E; Department of Leukemia, The University of Texas M.D. Anderson Cancer Center, Houston, Texas, USA., Kantarjian H; Department of Leukemia, The University of Texas M.D. Anderson Cancer Center, Houston, Texas, USA.
Publikováno v:
Cancer [Cancer] 2024 Oct 01; Vol. 130 (19), pp. 3344-3352. Date of Electronic Publication: 2024 May 28.
Autor:
Cuglievan B; Department of Pediatrics, The University of Texas MD Anderson Cancer Center, Houston, TX, USA. bcuglievan@mdanderson.org., Kantarjian H; Department of Leukemia, The University of Texas MD Anderson Cancer Center, Houston, TX, USA., Rubnitz JE; Department of Oncology, St Jude Children's Research Hospital, Memphis, TN, USA., Cooper TM; Cancer and Blood Disorders Center, Seattle Children's Hospital, University of Washington, Seattle, WA, USA., Zwaan CM; Princess Maxima Center for Pediatric Oncology, Utrecht, the Netherlands; Pediatric Oncology, Erasmus MC-Sophia Children's Hospital, Rotterdam, the Netherlands; The Innovative Therapies for Children with Cancer Consortium, Paris, France., Pollard JA; Department of Pediatrics, Harvard Medical School, Boston, MA, USA., DiNardo CD; Department of Leukemia, The University of Texas MD Anderson Cancer Center, Houston, TX, USA., Kadia TM; Department of Leukemia, The University of Texas MD Anderson Cancer Center, Houston, TX, USA., Guest E; Department of Pediatric Oncology, Children's Mercy, Kansas City, MO, USA., Short NJ; Department of Leukemia, The University of Texas MD Anderson Cancer Center, Houston, TX, USA., McCall D; Department of Pediatrics, The University of Texas MD Anderson Cancer Center, Houston, TX, USA., Daver N; Department of Leukemia, The University of Texas MD Anderson Cancer Center, Houston, TX, USA., Nunez C; Department of Pediatrics, The University of Texas MD Anderson Cancer Center, Houston, TX, USA., Haddad FG; Department of Leukemia, The University of Texas MD Anderson Cancer Center, Houston, TX, USA., Garcia M; Department of Pediatrics, The University of Texas MD Anderson Cancer Center, Houston, TX, USA., Bhalla KN; Department of Leukemia, The University of Texas MD Anderson Cancer Center, Houston, TX, USA., Maiti A; Department of Leukemia, The University of Texas MD Anderson Cancer Center, Houston, TX, USA., Catueno S; Department of Pediatrics, The University of Texas MD Anderson Cancer Center, Houston, TX, USA., Fiskus W; Department of Leukemia, The University of Texas MD Anderson Cancer Center, Houston, TX, USA., Carter BZ; Department of Leukemia, The University of Texas MD Anderson Cancer Center, Houston, TX, USA., Gibson A; Department of Pediatrics, The University of Texas MD Anderson Cancer Center, Houston, TX, USA., Roth M; Department of Pediatrics, The University of Texas MD Anderson Cancer Center, Houston, TX, USA., Khazal S; Division of Transplant and Cellular Therapy, Loma Linda University School of Medicine, Loma Linda, CA, USA., Tewari P; Department of Stem Cell Transplantation and Cellular Therapy, The University of Texas MD Anderson Cancer, Houston, TX, USA., Abbas HA; Department of Leukemia, The University of Texas MD Anderson Cancer Center, Houston, TX, USA., Bourgeois W; Department of Pediatrics, Harvard Medical School, Boston, MA, USA., Andreeff M; Department of Leukemia, The University of Texas MD Anderson Cancer Center, Houston, TX, USA., Shukla NN; Department of Pediatrics, Memorial Sloan Kettering Cancer Center, New York, NY, USA., Truong DD; Department of Sarcoma Medical Oncology, The University of Texas MD Anderson Cancer Center, Houston, TX, USA., Connors J; Department of Stem Cell Transplantation and Cellular Therapy, The University of Texas MD Anderson Cancer, Houston, TX, USA., Ludwig JA; Department of Sarcoma Medical Oncology, The University of Texas MD Anderson Cancer Center, Houston, TX, USA., Stutterheim J; Princess Máxima Center for Pediatric Oncology, Utrecht, the Netherlands., Salzer E; Princess Máxima Center for Pediatric Oncology, Utrecht, the Netherlands., Juul-Dam KL; Department of Pediatrics and Adolescent Medicine, Aarhus University Hospital, Aarhus, Denmark., Sasaki K; Department of Leukemia, The University of Texas MD Anderson Cancer Center, Houston, TX, USA., Mahadeo KM; Division of Pediatric Transplantation and Cellular Therapy, Duke University, Durham, NC, USA., Tasian SK; Department of Pediatrics and Abramson Cancer Center, University of Pennsylvania School of Medicine, Philadelphia, PA, USA., Borthakur G; Department of Leukemia, The University of Texas MD Anderson Cancer Center, Houston, TX, USA., Dickson S; Department of Pediatrics, The University of Texas MD Anderson Cancer Center, Houston, TX, USA., Jain N; Department of Leukemia, The University of Texas MD Anderson Cancer Center, Houston, TX, USA., Jabbour E; Department of Leukemia, The University of Texas MD Anderson Cancer Center, Houston, TX, USA., Meshinchi S; Clinical Research Division, Fred Hutchinson Cancer Research Center, Seattle, WA, USA., Garcia-Manero G; Department of Leukemia, The University of Texas MD Anderson Cancer Center, Houston, TX, USA., Ravandi F; Department of Leukemia, The University of Texas MD Anderson Cancer Center, Houston, TX, USA., Stein EM; Department of Leukemia, Memorial Sloan Kettering Cancer Center, New York, NY, USA., Kolb EA; Moseley Institute for Cancer and Blood Disorders, Nemours Children's Health, Wilmington, DE, USA., Issa GC; Department of Leukemia, The University of Texas MD Anderson Cancer Center, Houston, TX, USA.
Publikováno v:
Leukemia [Leukemia] 2024 Oct; Vol. 38 (10), pp. 2073-2084. Date of Electronic Publication: 2024 Aug 23.
Autor:
Gener-Ricos G; Department of Leukemia, The University of Texas MD Anderson Cancer Center, Houston, TX, USA., Bewersdorf JP; Leukemia Service, Department of Medicine, Memorial Sloan Kettering Cancer Center, New York, NY, USA., Loghavi S; Department of Hematopathology, The University of Texas MD Anderson Cancer Center, Houston, TX, USA., Bataller A; Department of Leukemia, The University of Texas MD Anderson Cancer Center, Houston, TX, USA., Goldberg AD; Leukemia Service, Department of Medicine, Memorial Sloan Kettering Cancer Center, New York, NY, USA., Sasaki K; Department of Leukemia, UT MD Anderson Cancer Center, Houston, USA., Famulare C; Leukemia Service, Department of Medicine, Memorial Sloan Kettering Cancer Center, New York, NY, USA., Takahashi K; Department of Leukemia, The University of Texas MD Anderson Cancer Center, Houston, TX, USA., Issa GC; Department of Leukemia, The University of Texas MD Anderson Cancer Center, Houston, TX, USA., Borthakur G; Department of Leukemia, The University of Texas MD Anderson Cancer Center, Houston, TX, USA., Kadia TM; Department of Leukemia, The University of Texas MD Anderson Cancer Center, Houston, TX, USA., Short NJ; Department of Leukemia, The University of Texas MD Anderson Cancer Center, Houston, TX, USA., Senapati J; Department of Leukemia, The University of Texas MD Anderson Cancer Center, Houston, TX, USA., Carter BZ; Department of Leukemia, The University of Texas MD Anderson Cancer Center, Houston, TX, USA., Patel KP; Department of Leukemia, The University of Texas MD Anderson Cancer Center, Houston, TX, USA., Kantarjian H; Department of Leukemia, The University of Texas MD Anderson Cancer Center, Houston, TX, USA., Andreeff M; Department of Leukemia, The University of Texas MD Anderson Cancer Center, Houston, TX, USA., Stein EM; Leukemia Service, Department of Medicine, Memorial Sloan Kettering Cancer Center, New York, NY, USA., DiNardo CD; Department of Leukemia, The University of Texas MD Anderson Cancer Center, Houston, TX, USA.
Publikováno v:
Leukemia & lymphoma [Leuk Lymphoma] 2024 Oct; Vol. 65 (10), pp. 1511-1515. Date of Electronic Publication: 2024 Jun 10.
Autor:
Short NJ; Department of Leukemia, The University of Texas MD Anderson Cancer Center, Houston, TX, USA. Electronic address: nshort@mdanderson.org., Nguyen D; Department of Leukemia, The University of Texas MD Anderson Cancer Center, Houston, TX, USA., Jabbour E; Department of Leukemia, The University of Texas MD Anderson Cancer Center, Houston, TX, USA., Senapati J; Department of Leukemia, The University of Texas MD Anderson Cancer Center, Houston, TX, USA., Zeng Z; Department of Leukemia, The University of Texas MD Anderson Cancer Center, Houston, TX, USA., Issa GC; Department of Leukemia, The University of Texas MD Anderson Cancer Center, Houston, TX, USA., Abbas H; Department of Leukemia, The University of Texas MD Anderson Cancer Center, Houston, TX, USA., Nasnas C; Department of Leukemia, The University of Texas MD Anderson Cancer Center, Houston, TX, USA., Qiao W; Department of Biostatistics, The University of Texas MD Anderson Cancer Center, Houston, TX, USA., Huang X; Department of Biostatistics, The University of Texas MD Anderson Cancer Center, Houston, TX, USA., Borthakur G; Department of Leukemia, The University of Texas MD Anderson Cancer Center, Houston, TX, USA., Chien K; Department of Leukemia, The University of Texas MD Anderson Cancer Center, Houston, TX, USA., Haddad FG; Department of Leukemia, The University of Texas MD Anderson Cancer Center, Houston, TX, USA., Pemmaraju N; Department of Leukemia, The University of Texas MD Anderson Cancer Center, Houston, TX, USA., Karrar OS; Department of Leukemia, The University of Texas MD Anderson Cancer Center, Houston, TX, USA., Nguyen D; Department of Leukemia, The University of Texas MD Anderson Cancer Center, Houston, TX, USA., Konopleva M; Department of Leukemia, The University of Texas MD Anderson Cancer Center, Houston, TX, USA; Department of Oncology, Montefiore Einstein Comprehensive Cancer Center, Bronx, NY, USA., Kantarjian H; Department of Leukemia, The University of Texas MD Anderson Cancer Center, Houston, TX, USA., Ravandi F; Department of Leukemia, The University of Texas MD Anderson Cancer Center, Houston, TX, USA.
Publikováno v:
The Lancet. Haematology [Lancet Haematol] 2024 Sep 17. Date of Electronic Publication: 2024 Sep 17.
Autor:
Hochhaus A; From Klinik für Innere Medizin II, Hematology/Oncology, Universitätsklinikum Jena and Comprehensive Cancer Center Central Germany, Campus Jena, Jena (A.H.), and the Department of Oncology and Hematology, Charité-Universitätsmedizin Berlin, Berlin (P.C.) - both in Germany; State Key Laboratory of Experimental Hematology, National Clinical Research Center for Blood Diseases, Institute of Hematology and Blood Diseases Hospital, Chinese Academy of Medical Sciences and Peking Union Medical College, Tianjin, China (J.W.); Uijeongbu Eulji Medical Center, Geumo-dong, Uijeongbu-si (D.-W.K.), and the Department of Internal Medicine, Seoul National University Hospital, Biomedical Research Institute, Cancer Research Institute, Seoul National University College of Medicine, Seoul (I.K.) - both in South Korea; Princess Margaret Cancer Centre, University Health Network, University of Toronto, Toronto (D.D.H.K.); the Department of Internal Medicine, Hematology and Oncology, University Hospital Brno, and Masaryk University - both in Brno, Czech Republic (J.M.); the Department of Hematology, Singapore General Hospital, Singapore (Y.-T.G.); the Department of Hematology, Akita University, Akita City, Japan (N.T.); the Hematology Department, Institut Bergonié, Bordeaux (G.E.), and Novartis Pharma, Paris (S.I.) - both in France; Rocky Mountain Cancer Centers, Boulder, CO (D.A.); the Department of Leukemia, University of Texas M.D. Anderson Cancer Center, Houston (G.C.I.); the University of Chicago, Chicago (R.A.L.); CML Patients Group, CML Advocates Network, Turin, Italy (F.B.); Novartis Pharmaceuticals, East Hanover, NJ (S.K.); Novartis Pharma, Basel, Switzerland (T.M., K.M., L.Y., M.H.); Georgia Cancer Center at Augusta University, Augusta (J.E.C.); and the South Australian Health and Medical Research Institute and University of Adelaide, Adelaide, SA, Australia (T.P.H.)., Wang J; From Klinik für Innere Medizin II, Hematology/Oncology, Universitätsklinikum Jena and Comprehensive Cancer Center Central Germany, Campus Jena, Jena (A.H.), and the Department of Oncology and Hematology, Charité-Universitätsmedizin Berlin, Berlin (P.C.) - both in Germany; State Key Laboratory of Experimental Hematology, National Clinical Research Center for Blood Diseases, Institute of Hematology and Blood Diseases Hospital, Chinese Academy of Medical Sciences and Peking Union Medical College, Tianjin, China (J.W.); Uijeongbu Eulji Medical Center, Geumo-dong, Uijeongbu-si (D.-W.K.), and the Department of Internal Medicine, Seoul National University Hospital, Biomedical Research Institute, Cancer Research Institute, Seoul National University College of Medicine, Seoul (I.K.) - both in South Korea; Princess Margaret Cancer Centre, University Health Network, University of Toronto, Toronto (D.D.H.K.); the Department of Internal Medicine, Hematology and Oncology, University Hospital Brno, and Masaryk University - both in Brno, Czech Republic (J.M.); the Department of Hematology, Singapore General Hospital, Singapore (Y.-T.G.); the Department of Hematology, Akita University, Akita City, Japan (N.T.); the Hematology Department, Institut Bergonié, Bordeaux (G.E.), and Novartis Pharma, Paris (S.I.) - both in France; Rocky Mountain Cancer Centers, Boulder, CO (D.A.); the Department of Leukemia, University of Texas M.D. Anderson Cancer Center, Houston (G.C.I.); the University of Chicago, Chicago (R.A.L.); CML Patients Group, CML Advocates Network, Turin, Italy (F.B.); Novartis Pharmaceuticals, East Hanover, NJ (S.K.); Novartis Pharma, Basel, Switzerland (T.M., K.M., L.Y., M.H.); Georgia Cancer Center at Augusta University, Augusta (J.E.C.); and the South Australian Health and Medical Research Institute and University of Adelaide, Adelaide, SA, Australia (T.P.H.)., Kim DW; From Klinik für Innere Medizin II, Hematology/Oncology, Universitätsklinikum Jena and Comprehensive Cancer Center Central Germany, Campus Jena, Jena (A.H.), and the Department of Oncology and Hematology, Charité-Universitätsmedizin Berlin, Berlin (P.C.) - both in Germany; State Key Laboratory of Experimental Hematology, National Clinical Research Center for Blood Diseases, Institute of Hematology and Blood Diseases Hospital, Chinese Academy of Medical Sciences and Peking Union Medical College, Tianjin, China (J.W.); Uijeongbu Eulji Medical Center, Geumo-dong, Uijeongbu-si (D.-W.K.), and the Department of Internal Medicine, Seoul National University Hospital, Biomedical Research Institute, Cancer Research Institute, Seoul National University College of Medicine, Seoul (I.K.) - both in South Korea; Princess Margaret Cancer Centre, University Health Network, University of Toronto, Toronto (D.D.H.K.); the Department of Internal Medicine, Hematology and Oncology, University Hospital Brno, and Masaryk University - both in Brno, Czech Republic (J.M.); the Department of Hematology, Singapore General Hospital, Singapore (Y.-T.G.); the Department of Hematology, Akita University, Akita City, Japan (N.T.); the Hematology Department, Institut Bergonié, Bordeaux (G.E.), and Novartis Pharma, Paris (S.I.) - both in France; Rocky Mountain Cancer Centers, Boulder, CO (D.A.); the Department of Leukemia, University of Texas M.D. Anderson Cancer Center, Houston (G.C.I.); the University of Chicago, Chicago (R.A.L.); CML Patients Group, CML Advocates Network, Turin, Italy (F.B.); Novartis Pharmaceuticals, East Hanover, NJ (S.K.); Novartis Pharma, Basel, Switzerland (T.M., K.M., L.Y., M.H.); Georgia Cancer Center at Augusta University, Augusta (J.E.C.); and the South Australian Health and Medical Research Institute and University of Adelaide, Adelaide, SA, Australia (T.P.H.)., Kim DDH; From Klinik für Innere Medizin II, Hematology/Oncology, Universitätsklinikum Jena and Comprehensive Cancer Center Central Germany, Campus Jena, Jena (A.H.), and the Department of Oncology and Hematology, Charité-Universitätsmedizin Berlin, Berlin (P.C.) - both in Germany; State Key Laboratory of Experimental Hematology, National Clinical Research Center for Blood Diseases, Institute of Hematology and Blood Diseases Hospital, Chinese Academy of Medical Sciences and Peking Union Medical College, Tianjin, China (J.W.); Uijeongbu Eulji Medical Center, Geumo-dong, Uijeongbu-si (D.-W.K.), and the Department of Internal Medicine, Seoul National University Hospital, Biomedical Research Institute, Cancer Research Institute, Seoul National University College of Medicine, Seoul (I.K.) - both in South Korea; Princess Margaret Cancer Centre, University Health Network, University of Toronto, Toronto (D.D.H.K.); the Department of Internal Medicine, Hematology and Oncology, University Hospital Brno, and Masaryk University - both in Brno, Czech Republic (J.M.); the Department of Hematology, Singapore General Hospital, Singapore (Y.-T.G.); the Department of Hematology, Akita University, Akita City, Japan (N.T.); the Hematology Department, Institut Bergonié, Bordeaux (G.E.), and Novartis Pharma, Paris (S.I.) - both in France; Rocky Mountain Cancer Centers, Boulder, CO (D.A.); the Department of Leukemia, University of Texas M.D. Anderson Cancer Center, Houston (G.C.I.); the University of Chicago, Chicago (R.A.L.); CML Patients Group, CML Advocates Network, Turin, Italy (F.B.); Novartis Pharmaceuticals, East Hanover, NJ (S.K.); Novartis Pharma, Basel, Switzerland (T.M., K.M., L.Y., M.H.); Georgia Cancer Center at Augusta University, Augusta (J.E.C.); and the South Australian Health and Medical Research Institute and University of Adelaide, Adelaide, SA, Australia (T.P.H.)., Mayer J; From Klinik für Innere Medizin II, Hematology/Oncology, Universitätsklinikum Jena and Comprehensive Cancer Center Central Germany, Campus Jena, Jena (A.H.), and the Department of Oncology and Hematology, Charité-Universitätsmedizin Berlin, Berlin (P.C.) - both in Germany; State Key Laboratory of Experimental Hematology, National Clinical Research Center for Blood Diseases, Institute of Hematology and Blood Diseases Hospital, Chinese Academy of Medical Sciences and Peking Union Medical College, Tianjin, China (J.W.); Uijeongbu Eulji Medical Center, Geumo-dong, Uijeongbu-si (D.-W.K.), and the Department of Internal Medicine, Seoul National University Hospital, Biomedical Research Institute, Cancer Research Institute, Seoul National University College of Medicine, Seoul (I.K.) - both in South Korea; Princess Margaret Cancer Centre, University Health Network, University of Toronto, Toronto (D.D.H.K.); the Department of Internal Medicine, Hematology and Oncology, University Hospital Brno, and Masaryk University - both in Brno, Czech Republic (J.M.); the Department of Hematology, Singapore General Hospital, Singapore (Y.-T.G.); the Department of Hematology, Akita University, Akita City, Japan (N.T.); the Hematology Department, Institut Bergonié, Bordeaux (G.E.), and Novartis Pharma, Paris (S.I.) - both in France; Rocky Mountain Cancer Centers, Boulder, CO (D.A.); the Department of Leukemia, University of Texas M.D. Anderson Cancer Center, Houston (G.C.I.); the University of Chicago, Chicago (R.A.L.); CML Patients Group, CML Advocates Network, Turin, Italy (F.B.); Novartis Pharmaceuticals, East Hanover, NJ (S.K.); Novartis Pharma, Basel, Switzerland (T.M., K.M., L.Y., M.H.); Georgia Cancer Center at Augusta University, Augusta (J.E.C.); and the South Australian Health and Medical Research Institute and University of Adelaide, Adelaide, SA, Australia (T.P.H.)., Goh YT; From Klinik für Innere Medizin II, Hematology/Oncology, Universitätsklinikum Jena and Comprehensive Cancer Center Central Germany, Campus Jena, Jena (A.H.), and the Department of Oncology and Hematology, Charité-Universitätsmedizin Berlin, Berlin (P.C.) - both in Germany; State Key Laboratory of Experimental Hematology, National Clinical Research Center for Blood Diseases, Institute of Hematology and Blood Diseases Hospital, Chinese Academy of Medical Sciences and Peking Union Medical College, Tianjin, China (J.W.); Uijeongbu Eulji Medical Center, Geumo-dong, Uijeongbu-si (D.-W.K.), and the Department of Internal Medicine, Seoul National University Hospital, Biomedical Research Institute, Cancer Research Institute, Seoul National University College of Medicine, Seoul (I.K.) - both in South Korea; Princess Margaret Cancer Centre, University Health Network, University of Toronto, Toronto (D.D.H.K.); the Department of Internal Medicine, Hematology and Oncology, University Hospital Brno, and Masaryk University - both in Brno, Czech Republic (J.M.); the Department of Hematology, Singapore General Hospital, Singapore (Y.-T.G.); the Department of Hematology, Akita University, Akita City, Japan (N.T.); the Hematology Department, Institut Bergonié, Bordeaux (G.E.), and Novartis Pharma, Paris (S.I.) - both in France; Rocky Mountain Cancer Centers, Boulder, CO (D.A.); the Department of Leukemia, University of Texas M.D. Anderson Cancer Center, Houston (G.C.I.); the University of Chicago, Chicago (R.A.L.); CML Patients Group, CML Advocates Network, Turin, Italy (F.B.); Novartis Pharmaceuticals, East Hanover, NJ (S.K.); Novartis Pharma, Basel, Switzerland (T.M., K.M., L.Y., M.H.); Georgia Cancer Center at Augusta University, Augusta (J.E.C.); and the South Australian Health and Medical Research Institute and University of Adelaide, Adelaide, SA, Australia (T.P.H.)., le Coutre P; From Klinik für Innere Medizin II, Hematology/Oncology, Universitätsklinikum Jena and Comprehensive Cancer Center Central Germany, Campus Jena, Jena (A.H.), and the Department of Oncology and Hematology, Charité-Universitätsmedizin Berlin, Berlin (P.C.) - both in Germany; State Key Laboratory of Experimental Hematology, National Clinical Research Center for Blood Diseases, Institute of Hematology and Blood Diseases Hospital, Chinese Academy of Medical Sciences and Peking Union Medical College, Tianjin, China (J.W.); Uijeongbu Eulji Medical Center, Geumo-dong, Uijeongbu-si (D.-W.K.), and the Department of Internal Medicine, Seoul National University Hospital, Biomedical Research Institute, Cancer Research Institute, Seoul National University College of Medicine, Seoul (I.K.) - both in South Korea; Princess Margaret Cancer Centre, University Health Network, University of Toronto, Toronto (D.D.H.K.); the Department of Internal Medicine, Hematology and Oncology, University Hospital Brno, and Masaryk University - both in Brno, Czech Republic (J.M.); the Department of Hematology, Singapore General Hospital, Singapore (Y.-T.G.); the Department of Hematology, Akita University, Akita City, Japan (N.T.); the Hematology Department, Institut Bergonié, Bordeaux (G.E.), and Novartis Pharma, Paris (S.I.) - both in France; Rocky Mountain Cancer Centers, Boulder, CO (D.A.); the Department of Leukemia, University of Texas M.D. Anderson Cancer Center, Houston (G.C.I.); the University of Chicago, Chicago (R.A.L.); CML Patients Group, CML Advocates Network, Turin, Italy (F.B.); Novartis Pharmaceuticals, East Hanover, NJ (S.K.); Novartis Pharma, Basel, Switzerland (T.M., K.M., L.Y., M.H.); Georgia Cancer Center at Augusta University, Augusta (J.E.C.); and the South Australian Health and Medical Research Institute and University of Adelaide, Adelaide, SA, Australia (T.P.H.)., Takahashi N; From Klinik für Innere Medizin II, Hematology/Oncology, Universitätsklinikum Jena and Comprehensive Cancer Center Central Germany, Campus Jena, Jena (A.H.), and the Department of Oncology and Hematology, Charité-Universitätsmedizin Berlin, Berlin (P.C.) - both in Germany; State Key Laboratory of Experimental Hematology, National Clinical Research Center for Blood Diseases, Institute of Hematology and Blood Diseases Hospital, Chinese Academy of Medical Sciences and Peking Union Medical College, Tianjin, China (J.W.); Uijeongbu Eulji Medical Center, Geumo-dong, Uijeongbu-si (D.-W.K.), and the Department of Internal Medicine, Seoul National University Hospital, Biomedical Research Institute, Cancer Research Institute, Seoul National University College of Medicine, Seoul (I.K.) - both in South Korea; Princess Margaret Cancer Centre, University Health Network, University of Toronto, Toronto (D.D.H.K.); the Department of Internal Medicine, Hematology and Oncology, University Hospital Brno, and Masaryk University - both in Brno, Czech Republic (J.M.); the Department of Hematology, Singapore General Hospital, Singapore (Y.-T.G.); the Department of Hematology, Akita University, Akita City, Japan (N.T.); the Hematology Department, Institut Bergonié, Bordeaux (G.E.), and Novartis Pharma, Paris (S.I.) - both in France; Rocky Mountain Cancer Centers, Boulder, CO (D.A.); the Department of Leukemia, University of Texas M.D. Anderson Cancer Center, Houston (G.C.I.); the University of Chicago, Chicago (R.A.L.); CML Patients Group, CML Advocates Network, Turin, Italy (F.B.); Novartis Pharmaceuticals, East Hanover, NJ (S.K.); Novartis Pharma, Basel, Switzerland (T.M., K.M., L.Y., M.H.); Georgia Cancer Center at Augusta University, Augusta (J.E.C.); and the South Australian Health and Medical Research Institute and University of Adelaide, Adelaide, SA, Australia (T.P.H.)., Kim I; From Klinik für Innere Medizin II, Hematology/Oncology, Universitätsklinikum Jena and Comprehensive Cancer Center Central Germany, Campus Jena, Jena (A.H.), and the Department of Oncology and Hematology, Charité-Universitätsmedizin Berlin, Berlin (P.C.) - both in Germany; State Key Laboratory of Experimental Hematology, National Clinical Research Center for Blood Diseases, Institute of Hematology and Blood Diseases Hospital, Chinese Academy of Medical Sciences and Peking Union Medical College, Tianjin, China (J.W.); Uijeongbu Eulji Medical Center, Geumo-dong, Uijeongbu-si (D.-W.K.), and the Department of Internal Medicine, Seoul National University Hospital, Biomedical Research Institute, Cancer Research Institute, Seoul National University College of Medicine, Seoul (I.K.) - both in South Korea; Princess Margaret Cancer Centre, University Health Network, University of Toronto, Toronto (D.D.H.K.); the Department of Internal Medicine, Hematology and Oncology, University Hospital Brno, and Masaryk University - both in Brno, Czech Republic (J.M.); the Department of Hematology, Singapore General Hospital, Singapore (Y.-T.G.); the Department of Hematology, Akita University, Akita City, Japan (N.T.); the Hematology Department, Institut Bergonié, Bordeaux (G.E.), and Novartis Pharma, Paris (S.I.) - both in France; Rocky Mountain Cancer Centers, Boulder, CO (D.A.); the Department of Leukemia, University of Texas M.D. Anderson Cancer Center, Houston (G.C.I.); the University of Chicago, Chicago (R.A.L.); CML Patients Group, CML Advocates Network, Turin, Italy (F.B.); Novartis Pharmaceuticals, East Hanover, NJ (S.K.); Novartis Pharma, Basel, Switzerland (T.M., K.M., L.Y., M.H.); Georgia Cancer Center at Augusta University, Augusta (J.E.C.); and the South Australian Health and Medical Research Institute and University of Adelaide, Adelaide, SA, Australia (T.P.H.)., Etienne G; From Klinik für Innere Medizin II, Hematology/Oncology, Universitätsklinikum Jena and Comprehensive Cancer Center Central Germany, Campus Jena, Jena (A.H.), and the Department of Oncology and Hematology, Charité-Universitätsmedizin Berlin, Berlin (P.C.) - both in Germany; State Key Laboratory of Experimental Hematology, National Clinical Research Center for Blood Diseases, Institute of Hematology and Blood Diseases Hospital, Chinese Academy of Medical Sciences and Peking Union Medical College, Tianjin, China (J.W.); Uijeongbu Eulji Medical Center, Geumo-dong, Uijeongbu-si (D.-W.K.), and the Department of Internal Medicine, Seoul National University Hospital, Biomedical Research Institute, Cancer Research Institute, Seoul National University College of Medicine, Seoul (I.K.) - both in South Korea; Princess Margaret Cancer Centre, University Health Network, University of Toronto, Toronto (D.D.H.K.); the Department of Internal Medicine, Hematology and Oncology, University Hospital Brno, and Masaryk University - both in Brno, Czech Republic (J.M.); the Department of Hematology, Singapore General Hospital, Singapore (Y.-T.G.); the Department of Hematology, Akita University, Akita City, Japan (N.T.); the Hematology Department, Institut Bergonié, Bordeaux (G.E.), and Novartis Pharma, Paris (S.I.) - both in France; Rocky Mountain Cancer Centers, Boulder, CO (D.A.); the Department of Leukemia, University of Texas M.D. Anderson Cancer Center, Houston (G.C.I.); the University of Chicago, Chicago (R.A.L.); CML Patients Group, CML Advocates Network, Turin, Italy (F.B.); Novartis Pharmaceuticals, East Hanover, NJ (S.K.); Novartis Pharma, Basel, Switzerland (T.M., K.M., L.Y., M.H.); Georgia Cancer Center at Augusta University, Augusta (J.E.C.); and the South Australian Health and Medical Research Institute and University of Adelaide, Adelaide, SA, Australia (T.P.H.)., Andorsky D; From Klinik für Innere Medizin II, Hematology/Oncology, Universitätsklinikum Jena and Comprehensive Cancer Center Central Germany, Campus Jena, Jena (A.H.), and the Department of Oncology and Hematology, Charité-Universitätsmedizin Berlin, Berlin (P.C.) - both in Germany; State Key Laboratory of Experimental Hematology, National Clinical Research Center for Blood Diseases, Institute of Hematology and Blood Diseases Hospital, Chinese Academy of Medical Sciences and Peking Union Medical College, Tianjin, China (J.W.); Uijeongbu Eulji Medical Center, Geumo-dong, Uijeongbu-si (D.-W.K.), and the Department of Internal Medicine, Seoul National University Hospital, Biomedical Research Institute, Cancer Research Institute, Seoul National University College of Medicine, Seoul (I.K.) - both in South Korea; Princess Margaret Cancer Centre, University Health Network, University of Toronto, Toronto (D.D.H.K.); the Department of Internal Medicine, Hematology and Oncology, University Hospital Brno, and Masaryk University - both in Brno, Czech Republic (J.M.); the Department of Hematology, Singapore General Hospital, Singapore (Y.-T.G.); the Department of Hematology, Akita University, Akita City, Japan (N.T.); the Hematology Department, Institut Bergonié, Bordeaux (G.E.), and Novartis Pharma, Paris (S.I.) - both in France; Rocky Mountain Cancer Centers, Boulder, CO (D.A.); the Department of Leukemia, University of Texas M.D. Anderson Cancer Center, Houston (G.C.I.); the University of Chicago, Chicago (R.A.L.); CML Patients Group, CML Advocates Network, Turin, Italy (F.B.); Novartis Pharmaceuticals, East Hanover, NJ (S.K.); Novartis Pharma, Basel, Switzerland (T.M., K.M., L.Y., M.H.); Georgia Cancer Center at Augusta University, Augusta (J.E.C.); and the South Australian Health and Medical Research Institute and University of Adelaide, Adelaide, SA, Australia (T.P.H.)., Issa GC; From Klinik für Innere Medizin II, Hematology/Oncology, Universitätsklinikum Jena and Comprehensive Cancer Center Central Germany, Campus Jena, Jena (A.H.), and the Department of Oncology and Hematology, Charité-Universitätsmedizin Berlin, Berlin (P.C.) - both in Germany; State Key Laboratory of Experimental Hematology, National Clinical Research Center for Blood Diseases, Institute of Hematology and Blood Diseases Hospital, Chinese Academy of Medical Sciences and Peking Union Medical College, Tianjin, China (J.W.); Uijeongbu Eulji Medical Center, Geumo-dong, Uijeongbu-si (D.-W.K.), and the Department of Internal Medicine, Seoul National University Hospital, Biomedical Research Institute, Cancer Research Institute, Seoul National University College of Medicine, Seoul (I.K.) - both in South Korea; Princess Margaret Cancer Centre, University Health Network, University of Toronto, Toronto (D.D.H.K.); the Department of Internal Medicine, Hematology and Oncology, University Hospital Brno, and Masaryk University - both in Brno, Czech Republic (J.M.); the Department of Hematology, Singapore General Hospital, Singapore (Y.-T.G.); the Department of Hematology, Akita University, Akita City, Japan (N.T.); the Hematology Department, Institut Bergonié, Bordeaux (G.E.), and Novartis Pharma, Paris (S.I.) - both in France; Rocky Mountain Cancer Centers, Boulder, CO (D.A.); the Department of Leukemia, University of Texas M.D. Anderson Cancer Center, Houston (G.C.I.); the University of Chicago, Chicago (R.A.L.); CML Patients Group, CML Advocates Network, Turin, Italy (F.B.); Novartis Pharmaceuticals, East Hanover, NJ (S.K.); Novartis Pharma, Basel, Switzerland (T.M., K.M., L.Y., M.H.); Georgia Cancer Center at Augusta University, Augusta (J.E.C.); and the South Australian Health and Medical Research Institute and University of Adelaide, Adelaide, SA, Australia (T.P.H.)., Larson RA; From Klinik für Innere Medizin II, Hematology/Oncology, Universitätsklinikum Jena and Comprehensive Cancer Center Central Germany, Campus Jena, Jena (A.H.), and the Department of Oncology and Hematology, Charité-Universitätsmedizin Berlin, Berlin (P.C.) - both in Germany; State Key Laboratory of Experimental Hematology, National Clinical Research Center for Blood Diseases, Institute of Hematology and Blood Diseases Hospital, Chinese Academy of Medical Sciences and Peking Union Medical College, Tianjin, China (J.W.); Uijeongbu Eulji Medical Center, Geumo-dong, Uijeongbu-si (D.-W.K.), and the Department of Internal Medicine, Seoul National University Hospital, Biomedical Research Institute, Cancer Research Institute, Seoul National University College of Medicine, Seoul (I.K.) - both in South Korea; Princess Margaret Cancer Centre, University Health Network, University of Toronto, Toronto (D.D.H.K.); the Department of Internal Medicine, Hematology and Oncology, University Hospital Brno, and Masaryk University - both in Brno, Czech Republic (J.M.); the Department of Hematology, Singapore General Hospital, Singapore (Y.-T.G.); the Department of Hematology, Akita University, Akita City, Japan (N.T.); the Hematology Department, Institut Bergonié, Bordeaux (G.E.), and Novartis Pharma, Paris (S.I.) - both in France; Rocky Mountain Cancer Centers, Boulder, CO (D.A.); the Department of Leukemia, University of Texas M.D. Anderson Cancer Center, Houston (G.C.I.); the University of Chicago, Chicago (R.A.L.); CML Patients Group, CML Advocates Network, Turin, Italy (F.B.); Novartis Pharmaceuticals, East Hanover, NJ (S.K.); Novartis Pharma, Basel, Switzerland (T.M., K.M., L.Y., M.H.); Georgia Cancer Center at Augusta University, Augusta (J.E.C.); and the South Australian Health and Medical Research Institute and University of Adelaide, Adelaide, SA, Australia (T.P.H.)., Bombaci F; From Klinik für Innere Medizin II, Hematology/Oncology, Universitätsklinikum Jena and Comprehensive Cancer Center Central Germany, Campus Jena, Jena (A.H.), and the Department of Oncology and Hematology, Charité-Universitätsmedizin Berlin, Berlin (P.C.) - both in Germany; State Key Laboratory of Experimental Hematology, National Clinical Research Center for Blood Diseases, Institute of Hematology and Blood Diseases Hospital, Chinese Academy of Medical Sciences and Peking Union Medical College, Tianjin, China (J.W.); Uijeongbu Eulji Medical Center, Geumo-dong, Uijeongbu-si (D.-W.K.), and the Department of Internal Medicine, Seoul National University Hospital, Biomedical Research Institute, Cancer Research Institute, Seoul National University College of Medicine, Seoul (I.K.) - both in South Korea; Princess Margaret Cancer Centre, University Health Network, University of Toronto, Toronto (D.D.H.K.); the Department of Internal Medicine, Hematology and Oncology, University Hospital Brno, and Masaryk University - both in Brno, Czech Republic (J.M.); the Department of Hematology, Singapore General Hospital, Singapore (Y.-T.G.); the Department of Hematology, Akita University, Akita City, Japan (N.T.); the Hematology Department, Institut Bergonié, Bordeaux (G.E.), and Novartis Pharma, Paris (S.I.) - both in France; Rocky Mountain Cancer Centers, Boulder, CO (D.A.); the Department of Leukemia, University of Texas M.D. Anderson Cancer Center, Houston (G.C.I.); the University of Chicago, Chicago (R.A.L.); CML Patients Group, CML Advocates Network, Turin, Italy (F.B.); Novartis Pharmaceuticals, East Hanover, NJ (S.K.); Novartis Pharma, Basel, Switzerland (T.M., K.M., L.Y., M.H.); Georgia Cancer Center at Augusta University, Augusta (J.E.C.); and the South Australian Health and Medical Research Institute and University of Adelaide, Adelaide, SA, Australia (T.P.H.)., Kapoor S; From Klinik für Innere Medizin II, Hematology/Oncology, Universitätsklinikum Jena and Comprehensive Cancer Center Central Germany, Campus Jena, Jena (A.H.), and the Department of Oncology and Hematology, Charité-Universitätsmedizin Berlin, Berlin (P.C.) - both in Germany; State Key Laboratory of Experimental Hematology, National Clinical Research Center for Blood Diseases, Institute of Hematology and Blood Diseases Hospital, Chinese Academy of Medical Sciences and Peking Union Medical College, Tianjin, China (J.W.); Uijeongbu Eulji Medical Center, Geumo-dong, Uijeongbu-si (D.-W.K.), and the Department of Internal Medicine, Seoul National University Hospital, Biomedical Research Institute, Cancer Research Institute, Seoul National University College of Medicine, Seoul (I.K.) - both in South Korea; Princess Margaret Cancer Centre, University Health Network, University of Toronto, Toronto (D.D.H.K.); the Department of Internal Medicine, Hematology and Oncology, University Hospital Brno, and Masaryk University - both in Brno, Czech Republic (J.M.); the Department of Hematology, Singapore General Hospital, Singapore (Y.-T.G.); the Department of Hematology, Akita University, Akita City, Japan (N.T.); the Hematology Department, Institut Bergonié, Bordeaux (G.E.), and Novartis Pharma, Paris (S.I.) - both in France; Rocky Mountain Cancer Centers, Boulder, CO (D.A.); the Department of Leukemia, University of Texas M.D. Anderson Cancer Center, Houston (G.C.I.); the University of Chicago, Chicago (R.A.L.); CML Patients Group, CML Advocates Network, Turin, Italy (F.B.); Novartis Pharmaceuticals, East Hanover, NJ (S.K.); Novartis Pharma, Basel, Switzerland (T.M., K.M., L.Y., M.H.); Georgia Cancer Center at Augusta University, Augusta (J.E.C.); and the South Australian Health and Medical Research Institute and University of Adelaide, Adelaide, SA, Australia (T.P.H.)., McCulloch T; From Klinik für Innere Medizin II, Hematology/Oncology, Universitätsklinikum Jena and Comprehensive Cancer Center Central Germany, Campus Jena, Jena (A.H.), and the Department of Oncology and Hematology, Charité-Universitätsmedizin Berlin, Berlin (P.C.) - both in Germany; State Key Laboratory of Experimental Hematology, National Clinical Research Center for Blood Diseases, Institute of Hematology and Blood Diseases Hospital, Chinese Academy of Medical Sciences and Peking Union Medical College, Tianjin, China (J.W.); Uijeongbu Eulji Medical Center, Geumo-dong, Uijeongbu-si (D.-W.K.), and the Department of Internal Medicine, Seoul National University Hospital, Biomedical Research Institute, Cancer Research Institute, Seoul National University College of Medicine, Seoul (I.K.) - both in South Korea; Princess Margaret Cancer Centre, University Health Network, University of Toronto, Toronto (D.D.H.K.); the Department of Internal Medicine, Hematology and Oncology, University Hospital Brno, and Masaryk University - both in Brno, Czech Republic (J.M.); the Department of Hematology, Singapore General Hospital, Singapore (Y.-T.G.); the Department of Hematology, Akita University, Akita City, Japan (N.T.); the Hematology Department, Institut Bergonié, Bordeaux (G.E.), and Novartis Pharma, Paris (S.I.) - both in France; Rocky Mountain Cancer Centers, Boulder, CO (D.A.); the Department of Leukemia, University of Texas M.D. Anderson Cancer Center, Houston (G.C.I.); the University of Chicago, Chicago (R.A.L.); CML Patients Group, CML Advocates Network, Turin, Italy (F.B.); Novartis Pharmaceuticals, East Hanover, NJ (S.K.); Novartis Pharma, Basel, Switzerland (T.M., K.M., L.Y., M.H.); Georgia Cancer Center at Augusta University, Augusta (J.E.C.); and the South Australian Health and Medical Research Institute and University of Adelaide, Adelaide, SA, Australia (T.P.H.)., Malek K; From Klinik für Innere Medizin II, Hematology/Oncology, Universitätsklinikum Jena and Comprehensive Cancer Center Central Germany, Campus Jena, Jena (A.H.), and the Department of Oncology and Hematology, Charité-Universitätsmedizin Berlin, Berlin (P.C.) - both in Germany; State Key Laboratory of Experimental Hematology, National Clinical Research Center for Blood Diseases, Institute of Hematology and Blood Diseases Hospital, Chinese Academy of Medical Sciences and Peking Union Medical College, Tianjin, China (J.W.); Uijeongbu Eulji Medical Center, Geumo-dong, Uijeongbu-si (D.-W.K.), and the Department of Internal Medicine, Seoul National University Hospital, Biomedical Research Institute, Cancer Research Institute, Seoul National University College of Medicine, Seoul (I.K.) - both in South Korea; Princess Margaret Cancer Centre, University Health Network, University of Toronto, Toronto (D.D.H.K.); the Department of Internal Medicine, Hematology and Oncology, University Hospital Brno, and Masaryk University - both in Brno, Czech Republic (J.M.); the Department of Hematology, Singapore General Hospital, Singapore (Y.-T.G.); the Department of Hematology, Akita University, Akita City, Japan (N.T.); the Hematology Department, Institut Bergonié, Bordeaux (G.E.), and Novartis Pharma, Paris (S.I.) - both in France; Rocky Mountain Cancer Centers, Boulder, CO (D.A.); the Department of Leukemia, University of Texas M.D. Anderson Cancer Center, Houston (G.C.I.); the University of Chicago, Chicago (R.A.L.); CML Patients Group, CML Advocates Network, Turin, Italy (F.B.); Novartis Pharmaceuticals, East Hanover, NJ (S.K.); Novartis Pharma, Basel, Switzerland (T.M., K.M., L.Y., M.H.); Georgia Cancer Center at Augusta University, Augusta (J.E.C.); and the South Australian Health and Medical Research Institute and University of Adelaide, Adelaide, SA, Australia (T.P.H.)., Yau L; From Klinik für Innere Medizin II, Hematology/Oncology, Universitätsklinikum Jena and Comprehensive Cancer Center Central Germany, Campus Jena, Jena (A.H.), and the Department of Oncology and Hematology, Charité-Universitätsmedizin Berlin, Berlin (P.C.) - both in Germany; State Key Laboratory of Experimental Hematology, National Clinical Research Center for Blood Diseases, Institute of Hematology and Blood Diseases Hospital, Chinese Academy of Medical Sciences and Peking Union Medical College, Tianjin, China (J.W.); Uijeongbu Eulji Medical Center, Geumo-dong, Uijeongbu-si (D.-W.K.), and the Department of Internal Medicine, Seoul National University Hospital, Biomedical Research Institute, Cancer Research Institute, Seoul National University College of Medicine, Seoul (I.K.) - both in South Korea; Princess Margaret Cancer Centre, University Health Network, University of Toronto, Toronto (D.D.H.K.); the Department of Internal Medicine, Hematology and Oncology, University Hospital Brno, and Masaryk University - both in Brno, Czech Republic (J.M.); the Department of Hematology, Singapore General Hospital, Singapore (Y.-T.G.); the Department of Hematology, Akita University, Akita City, Japan (N.T.); the Hematology Department, Institut Bergonié, Bordeaux (G.E.), and Novartis Pharma, Paris (S.I.) - both in France; Rocky Mountain Cancer Centers, Boulder, CO (D.A.); the Department of Leukemia, University of Texas M.D. Anderson Cancer Center, Houston (G.C.I.); the University of Chicago, Chicago (R.A.L.); CML Patients Group, CML Advocates Network, Turin, Italy (F.B.); Novartis Pharmaceuticals, East Hanover, NJ (S.K.); Novartis Pharma, Basel, Switzerland (T.M., K.M., L.Y., M.H.); Georgia Cancer Center at Augusta University, Augusta (J.E.C.); and the South Australian Health and Medical Research Institute and University of Adelaide, Adelaide, SA, Australia (T.P.H.)., Ifrah S; From Klinik für Innere Medizin II, Hematology/Oncology, Universitätsklinikum Jena and Comprehensive Cancer Center Central Germany, Campus Jena, Jena (A.H.), and the Department of Oncology and Hematology, Charité-Universitätsmedizin Berlin, Berlin (P.C.) - both in Germany; State Key Laboratory of Experimental Hematology, National Clinical Research Center for Blood Diseases, Institute of Hematology and Blood Diseases Hospital, Chinese Academy of Medical Sciences and Peking Union Medical College, Tianjin, China (J.W.); Uijeongbu Eulji Medical Center, Geumo-dong, Uijeongbu-si (D.-W.K.), and the Department of Internal Medicine, Seoul National University Hospital, Biomedical Research Institute, Cancer Research Institute, Seoul National University College of Medicine, Seoul (I.K.) - both in South Korea; Princess Margaret Cancer Centre, University Health Network, University of Toronto, Toronto (D.D.H.K.); the Department of Internal Medicine, Hematology and Oncology, University Hospital Brno, and Masaryk University - both in Brno, Czech Republic (J.M.); the Department of Hematology, Singapore General Hospital, Singapore (Y.-T.G.); the Department of Hematology, Akita University, Akita City, Japan (N.T.); the Hematology Department, Institut Bergonié, Bordeaux (G.E.), and Novartis Pharma, Paris (S.I.) - both in France; Rocky Mountain Cancer Centers, Boulder, CO (D.A.); the Department of Leukemia, University of Texas M.D. Anderson Cancer Center, Houston (G.C.I.); the University of Chicago, Chicago (R.A.L.); CML Patients Group, CML Advocates Network, Turin, Italy (F.B.); Novartis Pharmaceuticals, East Hanover, NJ (S.K.); Novartis Pharma, Basel, Switzerland (T.M., K.M., L.Y., M.H.); Georgia Cancer Center at Augusta University, Augusta (J.E.C.); and the South Australian Health and Medical Research Institute and University of Adelaide, Adelaide, SA, Australia (T.P.H.)., Hoch M; From Klinik für Innere Medizin II, Hematology/Oncology, Universitätsklinikum Jena and Comprehensive Cancer Center Central Germany, Campus Jena, Jena (A.H.), and the Department of Oncology and Hematology, Charité-Universitätsmedizin Berlin, Berlin (P.C.) - both in Germany; State Key Laboratory of Experimental Hematology, National Clinical Research Center for Blood Diseases, Institute of Hematology and Blood Diseases Hospital, Chinese Academy of Medical Sciences and Peking Union Medical College, Tianjin, China (J.W.); Uijeongbu Eulji Medical Center, Geumo-dong, Uijeongbu-si (D.-W.K.), and the Department of Internal Medicine, Seoul National University Hospital, Biomedical Research Institute, Cancer Research Institute, Seoul National University College of Medicine, Seoul (I.K.) - both in South Korea; Princess Margaret Cancer Centre, University Health Network, University of Toronto, Toronto (D.D.H.K.); the Department of Internal Medicine, Hematology and Oncology, University Hospital Brno, and Masaryk University - both in Brno, Czech Republic (J.M.); the Department of Hematology, Singapore General Hospital, Singapore (Y.-T.G.); the Department of Hematology, Akita University, Akita City, Japan (N.T.); the Hematology Department, Institut Bergonié, Bordeaux (G.E.), and Novartis Pharma, Paris (S.I.) - both in France; Rocky Mountain Cancer Centers, Boulder, CO (D.A.); the Department of Leukemia, University of Texas M.D. Anderson Cancer Center, Houston (G.C.I.); the University of Chicago, Chicago (R.A.L.); CML Patients Group, CML Advocates Network, Turin, Italy (F.B.); Novartis Pharmaceuticals, East Hanover, NJ (S.K.); Novartis Pharma, Basel, Switzerland (T.M., K.M., L.Y., M.H.); Georgia Cancer Center at Augusta University, Augusta (J.E.C.); and the South Australian Health and Medical Research Institute and University of Adelaide, Adelaide, SA, Australia (T.P.H.)., Cortes JE; From Klinik für Innere Medizin II, Hematology/Oncology, Universitätsklinikum Jena and Comprehensive Cancer Center Central Germany, Campus Jena, Jena (A.H.), and the Department of Oncology and Hematology, Charité-Universitätsmedizin Berlin, Berlin (P.C.) - both in Germany; State Key Laboratory of Experimental Hematology, National Clinical Research Center for Blood Diseases, Institute of Hematology and Blood Diseases Hospital, Chinese Academy of Medical Sciences and Peking Union Medical College, Tianjin, China (J.W.); Uijeongbu Eulji Medical Center, Geumo-dong, Uijeongbu-si (D.-W.K.), and the Department of Internal Medicine, Seoul National University Hospital, Biomedical Research Institute, Cancer Research Institute, Seoul National University College of Medicine, Seoul (I.K.) - both in South Korea; Princess Margaret Cancer Centre, University Health Network, University of Toronto, Toronto (D.D.H.K.); the Department of Internal Medicine, Hematology and Oncology, University Hospital Brno, and Masaryk University - both in Brno, Czech Republic (J.M.); the Department of Hematology, Singapore General Hospital, Singapore (Y.-T.G.); the Department of Hematology, Akita University, Akita City, Japan (N.T.); the Hematology Department, Institut Bergonié, Bordeaux (G.E.), and Novartis Pharma, Paris (S.I.) - both in France; Rocky Mountain Cancer Centers, Boulder, CO (D.A.); the Department of Leukemia, University of Texas M.D. Anderson Cancer Center, Houston (G.C.I.); the University of Chicago, Chicago (R.A.L.); CML Patients Group, CML Advocates Network, Turin, Italy (F.B.); Novartis Pharmaceuticals, East Hanover, NJ (S.K.); Novartis Pharma, Basel, Switzerland (T.M., K.M., L.Y., M.H.); Georgia Cancer Center at Augusta University, Augusta (J.E.C.); and the South Australian Health and Medical Research Institute and University of Adelaide, Adelaide, SA, Australia (T.P.H.)., Hughes TP; From Klinik für Innere Medizin II, Hematology/Oncology, Universitätsklinikum Jena and Comprehensive Cancer Center Central Germany, Campus Jena, Jena (A.H.), and the Department of Oncology and Hematology, Charité-Universitätsmedizin Berlin, Berlin (P.C.) - both in Germany; State Key Laboratory of Experimental Hematology, National Clinical Research Center for Blood Diseases, Institute of Hematology and Blood Diseases Hospital, Chinese Academy of Medical Sciences and Peking Union Medical College, Tianjin, China (J.W.); Uijeongbu Eulji Medical Center, Geumo-dong, Uijeongbu-si (D.-W.K.), and the Department of Internal Medicine, Seoul National University Hospital, Biomedical Research Institute, Cancer Research Institute, Seoul National University College of Medicine, Seoul (I.K.) - both in South Korea; Princess Margaret Cancer Centre, University Health Network, University of Toronto, Toronto (D.D.H.K.); the Department of Internal Medicine, Hematology and Oncology, University Hospital Brno, and Masaryk University - both in Brno, Czech Republic (J.M.); the Department of Hematology, Singapore General Hospital, Singapore (Y.-T.G.); the Department of Hematology, Akita University, Akita City, Japan (N.T.); the Hematology Department, Institut Bergonié, Bordeaux (G.E.), and Novartis Pharma, Paris (S.I.) - both in France; Rocky Mountain Cancer Centers, Boulder, CO (D.A.); the Department of Leukemia, University of Texas M.D. Anderson Cancer Center, Houston (G.C.I.); the University of Chicago, Chicago (R.A.L.); CML Patients Group, CML Advocates Network, Turin, Italy (F.B.); Novartis Pharmaceuticals, East Hanover, NJ (S.K.); Novartis Pharma, Basel, Switzerland (T.M., K.M., L.Y., M.H.); Georgia Cancer Center at Augusta University, Augusta (J.E.C.); and the South Australian Health and Medical Research Institute and University of Adelaide, Adelaide, SA, Australia (T.P.H.).
Publikováno v:
The New England journal of medicine [N Engl J Med] 2024 Sep 12; Vol. 391 (10), pp. 885-898. Date of Electronic Publication: 2024 May 31.
Autor:
Issa GC; Department of Leukemia, Division of Cancer Medicine, The University of Texas MD Anderson Cancer Center, Houston, TX., Aldoss I; Department of Hematology & Hematopoietic Cell Transplantation, City of Hope National Medical Center, Duarte, CA., Thirman MJ; Biological Sciences Division, The University of Chicago Medicine, Chicago, IL., DiPersio J; John T. Milliken Department of Medicine, Division of Oncology, Washington University School of Medicine, St Louis, MO., Arellano M; Winship Cancer Institute, Emory University School of Medicine, Atlanta, GA., Blachly JS; Arthur G. James Cancer Hospital and Richard J. Solove Research Institute, The Ohio State University, Columbus, OH., Mannis GN; Division of Hematology, Stanford University School of Medicine, Stanford, CA., Perl A; Perelman School of Medicine, University of Pennsylvania, Philadelphia, PA., Dickens DS; University of Iowa Stead Family Children's Hospital, Iowa City, IA., McMahon CM; UCHealth Blood Disorders and Cell Therapies Center, University of Colorado School of Medicine, Aurora, CO., Traer E; Knight Cancer Institute, Oregon Health & Science University, Portland, OR., Zwaan CM; Princess Máxima Center for Pediatric Oncology, Utrecht, and Erasmus MC-Sophia Children's Hospital, Rotterdam, the Netherlands., Grove CS; Department of Haematology, Sir Charles Gairdner Hospital, Nedlands, Australia., Stone R; Department of Medical Oncology, Dana-Farber Cancer Institute, Boston, MA., Shami PJ; University of Utah Huntsman Cancer Institute, Salt Lake City, UT., Mantzaris I; Department of Oncology, Montefiore Einstein Comprehensive Cancer Center, Bronx, NY., Greenwood M; Department of Haematology, Royal North Shore Hospital, The University of Sydney, Sydney, New South Wales, Australia., Shukla N; Department of Pediatrics, Memorial Sloan Kettering Cancer Center, New York, NY., Cuglievan B; Department of Leukemia, Division of Cancer Medicine, The University of Texas MD Anderson Cancer Center, Houston, TX., Kovacsovics T; City of Hope Phoenix, Goodyear, AZ., Gu Y; Syndax Pharmaceuticals, Inc, Waltham, MA., Bagley RG; Syndax Pharmaceuticals, Inc, Waltham, MA., Madigan K; Syndax Pharmaceuticals, Inc, Waltham, MA., Chudnovsky Y; Syndax Pharmaceuticals, Inc, Waltham, MA., Nguyen HV; Syndax Pharmaceuticals, Inc, Waltham, MA., McNeer N; Syndax Pharmaceuticals, Inc, Waltham, MA., Stein EM; Department of Pediatrics, Memorial Sloan Kettering Cancer Center, New York, NY.
Publikováno v:
Journal of clinical oncology : official journal of the American Society of Clinical Oncology [J Clin Oncol] 2024 Aug 09, pp. JCO2400826. Date of Electronic Publication: 2024 Aug 09.